Pain Clinic Survey 10, Urine
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
This assay was designed to test for and confirm by gas chromatography-mass spectrometry (GC-MS) the following:
This test uses the simple screening technique described under IDOAU / Drug Abuse Survey, Urine, which involves immunologic testing for drugs by class. Oxycodone is not detected well with the opiate screening assay; therefore, OPATU / Opiates, Urine is included to detect this drug. All positive screening results are confirmed by GC-MS, and quantitated, before a positive result is reported.
Detecting drug use involving amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, propoxyphene, and tetrahydrocannabinol
This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.
A positive result derived by this testing indicates that the patient has used 1 of the drugs detected by this technique in the recent past. See individual tests (eg, AMPHU / Amphetamines, Urine) for more information.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at http://www.mayomedicallaboratories.com/articles/drug-book/index.html
Creatinine and specific gravity are measured as indicators of specimen dilution.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Not intended for use in employment-related testing.
For situations where chain-of-custody is required, a Chain-of-Custody Kit (Supply T282) is available. See COCH / Chain-of-Custody Processing.
The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/OTC, Serum or PDSU / Drug Screen, Prescription/OTC, Urine).
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Screening cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Methadone: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Propoxyphene: 300 ng/mL
Tetrahydrocannabinol carboxylic acid: 20 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. Physicians' Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006
2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006
3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company, 2011, pp 1109-1188